• Understanding 340B Programs: An Interview with Antonio Ciaccia, CEO, 46brooklyn Research

  • Apr 25 2024
  • Duración: 47 m
  • Podcast

Understanding 340B Programs: An Interview with Antonio Ciaccia, CEO, 46brooklyn Research Por arte de portada

Understanding 340B Programs: An Interview with Antonio Ciaccia, CEO, 46brooklyn Research

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • In this episode, we explore the 340B Drug Pricing Program, an essential yet complex component of the American drug supply landscape that aims to enable healthcare entities to offer more affordable medication to underserved populations. We interview Antonio Ciaccia, a drug pricing and 340B expert who provides an in-depth look at how the program works, its financial incentives, and how stakeholders have exploited this well-intentioned program, all to the detriment of patients.

    • Antonio Ciaccia, President, 3 Axis Advisors and CEO, 46brooklyn Research, an Ohio non-profit Corporation
    • 46brooklyn
    • Ohio Pharmacist Association
    • 3 Axis Advisors
    • Medicaid
    • 340B Program
    • 340B Litigation
    • 340 Eligibility, HRSA
    • Covered Entities
    • Medicaid Drug Rebate Program
    • Obamacare
    • Indian Health Service
    • "Money from Sick People," Report from 46Brooklyn
    • Medicare
    • Pharmacy Benefit Managers (PBMs)
    • Jamie Robinson, Health Economist

    Medical terminology referenced in this episode:

    • Novolog

    Questions or comments?
    Email us at comments@prescriptionforbetteraccess.com.
    Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.
    Más Menos
activate_primeday_promo_in_buybox_DT
Enfermedades Físicas Hygiene & Healthy Living Ciencias Biológicas
Más Menos

Lo que los oyentes dicen sobre Understanding 340B Programs: An Interview with Antonio Ciaccia, CEO, 46brooklyn Research

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles